Company / Cash & Equivalents
Solventum Cash & Equivalents History
FY2023-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$878.0M
FY2025
5-year range
$194.0M / $878.0M
FY2023-FY2025
Trend
+15.2%
vs FY2024
Sector context
#32 of 148
Health Care
What the data says
Solventum's cash & equivalents of $878M is higher than 78% of companies in the Health Care sector (FY2025). Improved from $194M to $878M over the past 2 years.
Based on SEC 10-K filings.
$878M in FY2025. Top quartile in the Health Care sector.
Improved from $194M to $878M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Top 22% in Health CareTop 22% of 148This company $878.0M Sector average $1.2B
▼
-25.4% below sector average
Key checks
Key Insights
- In FY2025, cash & equivalents increased 15.2% year-over-year.
- Ranks #32 out of 148 companies in the Health Care sector.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 30.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $878.0M | +15.2% |
| FY2024 | $762.0M | +292.8% |
| FY2023 | $194.0M | - |
| FY2022 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026